Sugi Predict

Sugi Predict / Compounds / SCHEMBL128134

SCHEMBL128134

SCHEMBL128134

CN(C)C(=O)c1cccc(C(N)=O)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 9/20 0.57
▸ MEN1 O00255 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ TSHR P16473 2/20 0.46
▸ POLB P06746 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ RECQL P46063 1/20 0.46
▸ BLM P54132 1/20 0.46
▸ PMP22 Q01453 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ ERN1 O75460 2/20 0.46
▸ PARP15 Q460N3 2/20 0.46
▸ PARP10 Q53GL7 2/20 0.46
▸ F10 P00742 2/20 0.46
▸ PMM2 O15305 1/20 0.46
▸ MPI P34949 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29562303 1.00 PARP1 (0.57) PARP1MEN1KMT2ATSHRPOLB
SCHEMBL7406706 0.89 MEN1 (0.55) MEN1KMT2ACYP3A4TDP1L3MBTL1
SCHEMBL36694 0.82 PARP1 (0.73) PARP1MEN1KMT2ATSHRPOLB
SCHEMBL31021028 0.82 PARP1 (0.73) PARP1MEN1KMT2ATSHRPOLB
SCHEMBL8881536 0.82 LCK (0.58) PARP1HSD17B10PARP10PARP2
SCHEMBL8271457 0.82 PARP1 (0.54) PARP1MEN1KMT2ATSHRPOLB
SCHEMBL31365131 0.82 MEN1 (0.49) MEN1KMT2ATDP1ERN1PMM2
SCHEMBL1255459 0.82 MEN1 (0.53) MEN1KMT2ATSHRPOLBMAPT
SCHEMBL12640103 0.82 MEN1 (0.49) MEN1KMT2ATDP1ERN1PMM2
Methane SCHEMBL688609 0.80 PARP1 (0.70) PARP1MEN1KMT2ATSHRPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8236795-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2012-08-07 — — US claimed
US-20120039815-A9 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2012-02-16 — — US claimed
US-20110256068-A1 CONTRAST MEDIA COMPOSITIONS GE HEALTHCARE AS (NO) 2011-10-20 — — US claimed
US-20110052504-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2011-03-03 — — US claimed
US-20110008263-A1 CONTRAST AGENTS GE HEALTHCARE AS (NO) 2011-01-13 — — US claimed
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORPORATION (US) 2010-10-07 — — US claimed
US-7696202-B2 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2010-04-13 — — US claimed
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome ELAN PHARMACEUTICALS, INC. 2008-07-03 — — US claimed
EP-1819341-A2 IL-12 MODULATORY COMPOUNDS Synta Pharmaceuticals Corporation (US) 2007-08-22 — — EP claimed
US-20070155877-A1 Polyamide resin composition E. I. DU PONT DE NEMOURS AND COMPANY 2007-07-05 — — US claimed
US-20060223996-A1 IL-12 modulatory compounds SYNTA PHARMACEUTICALS CORP. (US) 2006-10-05 — — US claimed
WO-2006053227-A2 IL-12 MODULATORY COMPOUNDS SYNTA PHARMACEUTICALS CORP. (US) 2006-05-18 — — WO claimed
WO-2026089784-A2 COMPOUNDS AND COMPOSITIONS FOR CONJUGATION TO BIOLIGANDS FOR IMAGING AND RADIOPHARMACEUTICAL APPLICATIONS THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) 2026-04-30 — — WO disclosed
EP-4337441-B1 IMPROVED METHOD FOR FORMING THERMOPLASTIC ADDITIVE MANUFACTURING POWDERS LUMAS POLYMERS LLC (US) 2025-11-26 — — EP disclosed
US-12180343-B2 Thermoplastic polymers and method to make them LUMAS POLYMERS LLC (US) 2024-12-31 — — US disclosed
WO-2024226710-A1 METHOD TO FORM COMPOSITE PARTICLES AND ARTICLES MADE THEREFROM Jabil Inc. (US) 2024-10-31 — — WO disclosed
EP-0395414-A1 Crystalline polyphtalamide composition having improved heat resistance properties AMOCO CORPORATION (US) 1990-10-31 — — EP disclosed
EP-0361636-A2 Polyamide-polyarylene sulfide blends AMOCO CORPORATION (US) 1990-04-04 — — EP disclosed
EP-0279578-A1 Moldable thermoplastic polyamide composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-08-24 — — EP disclosed
EP-0234819-A2 Thermoplastic resin compositions SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1987-09-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223996-A1 IL-12 modulatory compounds IL2, IL4, IFNG PARP1 3673/4885MEN1 4303/4885KMT2A 3672/4885
US-20120039815-A9 CONTRAST AGENTS C5, TXN, CBR3 PARP1 3727/4885MEN1 426/4885KMT2A 4321/4885
US-20110052504-A1 CONTRAST AGENTS C5, TXN, CBR3 PARP1 3727/4885MEN1 426/4885KMT2A 4321/4885
US-20110008263-A1 CONTRAST AGENTS C5, C1R, C3AR1 PARP1 2938/4885MEN1 159/4885KMT2A 4404/4885
US-20110256068-A1 CONTRAST MEDIA COMPOSITIONS FPR1, FPR3, TPO PARP1 3384/4885MEN1 43/4885KMT2A 4533/4885
US-20100256132-A1 IL-12 MODULATORY COMPOUNDS IL2, IL4, IFNG PARP1 3673/4885MEN1 4303/4885KMT2A 3672/4885
US-20080161325-A1 e.g. N1-[3-amino-4-(3,5-difluorophenyl)-2-hydroxybutyl]-3-(butylsulfonyl)-N1-(3-ethylbenzyl)-D-alaninamide dihydrochloride; inhibitors of amyloid beta-secretase enzyme; neurodegenerative diseases: Alzheimer's, Parkinson's diseases, Down's syndrome BACE1, APP, BACE2 PARP1 1394/4885MEN1 1613/4885KMT2A 2573/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.